Impax throws down Oxycontin gauntlet; Pfizer's Lyrica gets boost in guidelines;

@FiercePharma: J&J agrees to pay $70M in corruption probe. Story | Follow @FiercePharma

> Impax Laboratories is challenging the patents on Purdue Pharma's painkiller Oxycontin as it seeks to sell a generic version of the drug. Report

> New guidelines suggest Pfizer's Lyrica for treating diabetes patients with nerve-pain symptoms, because it is the best-studied drug for the condition, among 13 underutilized treatments. Story

> A society for Canadian ob/gyns allowed contraceptive maker Bayer to write its prescribing guidelines for hormone-based birth control pills, and it failed to disclose that conflict of interest, according to the Canadian Medical Association Journal. Article

> Merck said the FDA has approved its drug to treat skin cancer in patients with node-positive melanoma following removal of the affected part. News

> A West Virginia man has been sentenced to more than 31 years in prison for kidnapping and robbing a medical supply delivery driver at gunpoint. Report

> The UK's General Medical Council has proposed, for the first time, that doctors may prescribe a cheaper off-label alternative to a licensed medicine, provided it is approved in authoritative clinical guidelines and is equally safe and effective. Item

> Indian firm Dr Reddy's has opened its new pharma services site in Cambridge, England. Story

> Chilean specialty branded generics manufacturer Corporacion Farmaceutica Recalcine, or CFR, will debut on the local stock exchange May 5. Report

> Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, announced the appointment of Ken Jones as its president and CEO. Item

> AstraZeneca announced that it purchased for cancellation 129,032 ordinary shares at a price of 2967 pence per share. News

Biotech News

 @FierceBiotech:  Intercell shares nosedive as investigators slam brakes on patient recruitment. Story | Follow @FierceBiotech

 @JohnCFierce: So Inspiration, now in Ireland scouting plants, recently raised its financing to $247 million. News | Follow @JohnCFierce

 > Teva's oral MS drug data disappoints the analysts. News 

> Outgoing Genzyme CEO Termeer hops on to AVEO board. Report 

> Exelixis spurs takeover rumors with Goldman ploy. Story

Biotech Research News

> WHO warns of impending drug-resistance crisis. Article 

> Dogs help humans narrow down lymphoma genes. Report 

> Alzheimer's mice at center of academic vs. property rights. Story 

> Two genes found for caffeine cravings. Item 

> Visionary scientists grow retina from stem cells. Report 

Manufacturing News

> Gartner taps TraceLink for supply chain kudos. Article 

> CMO Lonza builds in UK for bio business. Item 

> Serialization mandates highlight need for expertise. News

> GSK moves bioprocessing to UK from India. Story 

> TraceLink wins supply chain kudos. News 

And Finally... British scientists have discovered how antidepressants make new brain cells--a finding that should help drug researchers develop better and more efficient medicines to fight depression. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.